Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2021 | Story Ruan Bruwer | Photo Roger Sedres (Gallo Images)
Louzanne Coetzee and her guide Estean Badenhorst won the silver medal in the 1 500 m in a new African time at the Paralympics in Tokyo on Monday.

It’s been eight years of waiting, but Louzanne Coetzee will finally hang a medal around her neck, and this on the biggest sporting stage in the world.

Coetzee won the silver medal in the 1 500 m women’s T11 final at the Paralympics in Tokyo on Monday (30 August 2021) morning. In the process, she and her guide, Estean Badenhorst, set a new African record (4:40.96).

They are both former University of the Free State (UFS) students, and Coetzee is a resident on the Bloemfontein Campus. 

“I have been competing for eight years and this is my first medal. I’m just overwhelmed. I couldn’t have asked for a better race, a better guide, and better preparation. I’m just very thankful for how everything went down,” Coetzee said.
The race took place at 32 degrees with a humidity percentage of 70 plus. Coetzee’s time was only 2.04 seconds off the previous world record. 

She has had a stunning Games so far. In Sunday’s heat, she improved her personal best from 4:51.65 to 4:49.24 and ran another eight seconds quicker on Monday.

It was also a personal triumph for Coetzee, who experienced the disappointment of being disqualified five years ago at the Rio Games, after a ruling that her guide had stepped in front of her. 

Prof Francis Petersen, UFS Rector and Vice-Chancellor, saluted Coetzee. “We are tremendously proud of what she has achieved throughout her athletics career. She has represented the country numerous times at international sport events and winning a silver medal and setting a new African record is the culmination of hard work and exceptional endurance.” 

“The entire university community was rooting for her; she has done us and her country extremely proud,” Prof Petersen said.

Coetzee still has the T12 marathon on Sunday on her schedule.

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept